Job Trends
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.
Job listings in the area have ticked up in the last month. These seven companies are hiring in South San Francisco right now, including scientist and clinical roles.
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Career Advice
Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to employment attorney Howard Matalon, JD, partner at OlenderFeldman, on how to evaluate the fine print of an employment agreement.
THE LATEST
Pfizer is planning to hire 200 new staffers and another 200 replacement workers in Michigan.
The new space is located just a few miles from Kendall Square that has become the hub of the Boston biotech industry.
Less than one month after announcing plans for construction of a South Carolina manufacturing facility, Arthrex announces its plans for the expansion of its global headquarters in Florida.
Abeona Therapeutics has plans to expand its facilities and hire an additional 25 to 40 employees.
Sangamo is moving its corporate headquarters to a new site at Oyster Point in Brisbane, CA.
The cash will allow the company to hire scientists to conduct preclinical research into a potential treatment for DMD.
A little more than one year after securing $130M in financing, molecular technology company Zymergen has expanded beyond the Golden State to the Emerald City, Seattle.
The company plans to invest nearly $10 million over five years to establish operations in Indiana.
CryoPort handles the products for more than 172 of the more than 800 immunotherapy trials underway.
Want to work for a company having a growth spurt?